These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 16298909

  • 1. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
    Chinetti-Gbaguidi G, Fruchart JC, Staels B.
    Biomarkers; 2005 Nov; 10 Suppl 1():S30-6. PubMed ID: 16298909
    [Abstract] [Full Text] [Related]

  • 2. Measuring biomarkers to assess the therapeutic effects of PPAR agonists?
    Chinetti-Gbaguidi G, Staels B.
    Pharmacogenomics; 2007 Nov; 8(11):1567-80. PubMed ID: 18034622
    [Abstract] [Full Text] [Related]

  • 3. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM, Schiffrin EL.
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [Abstract] [Full Text] [Related]

  • 4. PPAR agonists and the metabolic syndrome.
    Staels B.
    Therapie; 2007 Jul; 62(4):319-26. PubMed ID: 17983557
    [Abstract] [Full Text] [Related]

  • 5. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B, Staels B.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [Abstract] [Full Text] [Related]

  • 6. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B, Fonseca V.
    Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
    [Abstract] [Full Text] [Related]

  • 7. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
    Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ.
    Am J Ther; 2007 Jul; 14(1):49-62. PubMed ID: 17303976
    [Abstract] [Full Text] [Related]

  • 8. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Fiévet C, Fruchart JC, Staels B.
    Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
    [Abstract] [Full Text] [Related]

  • 9. [Fibrates and markers of inflammation].
    Broncel M.
    Pol Merkur Lekarski; 2007 Jan; 22(127):58-61. PubMed ID: 17477093
    [Abstract] [Full Text] [Related]

  • 10. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
    Hennuyer N, Tailleux A, Torpier G, Mezdour H, Fruchart JC, Staels B, Fiévet C.
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1897-902. PubMed ID: 15994444
    [Abstract] [Full Text] [Related]

  • 11. Glitazones in the treatment of cardiovascular risk factors.
    Bouhlel MA, Chinetti-Gbaguidi G, Staels B.
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():7-13. PubMed ID: 18001313
    [Abstract] [Full Text] [Related]

  • 12. Differential antiatherogenic effects of PPARalpha versus PPARgamma agonists: should we be surprised?
    Camejo G.
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1763-4. PubMed ID: 16127025
    [No Abstract] [Full Text] [Related]

  • 13. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
    Gervois P, Fruchart JC, Staels B.
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
    [Abstract] [Full Text] [Related]

  • 14. Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
    Pinelli A, Godio C, Laghezza A, Mitro N, Fracchiolla G, Tortorella V, Lavecchia A, Novellino E, Fruchart JC, Staels B, Crestani M, Loiodice F.
    J Med Chem; 2005 Aug 25; 48(17):5509-19. PubMed ID: 16107150
    [Abstract] [Full Text] [Related]

  • 15. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence.
    Zambon A, Gervois P, Pauletto P, Fruchart JC, Staels B.
    Arterioscler Thromb Vasc Biol; 2006 May 25; 26(5):977-86. PubMed ID: 16424352
    [Abstract] [Full Text] [Related]

  • 16. PPARs as therapeutic targets in cardiovascular disease.
    van Bilsen M, van Nieuwenhoven FA.
    Expert Opin Ther Targets; 2010 Oct 25; 14(10):1029-45. PubMed ID: 20854178
    [Abstract] [Full Text] [Related]

  • 17. [Nuclear receptors PPAR as a drug target in metabolic disorders].
    Stolarczyk M, Gutman W, Derlacz RA.
    Postepy Biochem; 2011 Oct 25; 57(2):207-14. PubMed ID: 21913422
    [Abstract] [Full Text] [Related]

  • 18. Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma.
    Rau O, Syha Y, Zettl H, Kock M, Bock A, Schubert-Zsilavecz M.
    Arch Pharm (Weinheim); 2008 Mar 25; 341(3):191-5. PubMed ID: 18275039
    [Abstract] [Full Text] [Related]

  • 19. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
    Libby P, Plutzky J.
    Am J Cardiol; 2007 Feb 19; 99(4A):27B-40B. PubMed ID: 17307056
    [Abstract] [Full Text] [Related]

  • 20. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?
    Becker J, Delayre-Orthez C, Frossard N, Pons F.
    Fundam Clin Pharmacol; 2006 Oct 19; 20(5):429-47. PubMed ID: 16968414
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.